期刊文献+

上皮性卵巢癌组织中核受体共激活因子蛋白表达水平及其与孕激素受体表达的相关性研究 被引量:3

Relationship between expression level of amplified in breast cancer 1 protein in epithelial ovarian cancer tissues and correlation of its level with expression of progesterone receptor
原文传递
导出
摘要 目的观察上皮性卵巢癌组织中核受体共激活因子(AIB1)蛋白表达水平及其与孕激素受体(PR)表达的相关性。方法将我院收治的23例良性卵巢肿瘤患者作为良性组,21例恶性卵巢肿瘤患者作为恶性组,另外选取25例体检志愿者作为健康组。观察3组受试者AIB1蛋白及PR表达情况,并分析其与临床病理特征的关系及两者的相关性。结果与健康组AIB1阳性表达率为8.00%比较,良性组和恶性组AIB1阳性表达率分别30.43%,66.67%,组间比较差异有统计学意义(P〈0.05);健康组、良性组和恶性组3组PR阳性表达率44.00%,47.83%,47.62%,3组比较差异无统计学意义(P〉0.05)。低分化、Ⅲ~Ⅳ期、淋巴结转移、浆液型卵巢癌上皮性卵巢癌组织中AIB1蛋白阳性表达率分别为70.00%,84.62%,91.67%,85.71%;同时这4种情况的PR阳性表达率分别为60.00%,53.85%,66.67%,57.14%,与高中分化、Ⅰ~Ⅱ期、无淋巴结转移及非浆液型比较,差异均有统计学意义(P〈0.05)。AIB1蛋白表达与PR表达之间无相关性(r=0.002,P〉0.05)。结论 AIB1蛋白表达水平与上皮性卵巢癌组织的关系密切,但和PR表达之间无相关性。 Objective To explore the relationship between expression level of amplified in breast cancer 1( AIB1) protein in epithelial ovarian cancer tissues and expression of progesterone receptor( PR). Methods Twenty- three cases of patients with benign ovarian tumor treated in our hospital were as the benign group,another twenty- one cases of patients with malignant ovarian tumor were as the malignant group,then twenty- five cases of healthy volunteers were selected as the healthy group. The expressions of AIB1 protein and PR in the three groups were observed. The correlations between the expression and clinical pathological characteristics were analysed. Results Compared with those in the healthy group,the positive- expression rates of AIB1 in the benign group and malignant group were 30. 43% and 66. 67%,which were obviously increased( P 〈 0. 05). Compared with that in the benign group,the positive- expression rate of AIB1 in the malignant group was 66. 67%,which was obviously increased( P 〈 0. 05). The differences in the positive- expression rates of PR among the three groups were not statistically significant with 44. 00%,47. 83%,47. 62%,respectively( P 〉 0. 05).The positive- expression rates of AIB1 in tissues with low differentiation,stage Ⅲ to Ⅳ,lymph node metastasis,serous type of epithelial ovarian cancer were 70. 00%,84. 62%,91. 67% and 85. 71%. And the positive- expression rates of PR in that were 60. 00%,53. 85%,66. 67% and 57. 14%,which were obviously lower than those in the tissues with high and moderate differentiation,stageⅠto Ⅱ,non lymph node metastasis and non serous type( P 〈 0. 05). There was no correlation between the expressions of AIB1 protein and PR( r = 0. 002,P 〉 0. 05). Conclusion The expression level of AIB1 protein is closely related to epithelial ovarian cancer,but there is no correlation with PR expression.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2016年第18期1673-1676,共4页 The Chinese Journal of Clinical Pharmacology
基金 湖北省卫生厅青年科技人才基金资助项目(2013-2014:QJX2012-13)
关键词 上皮性卵巢癌 核受体共激活因子 孕激素受体 免疫组化学 epithelial ovarian cancer amplified in breast cancer 1 progesterone receptor immunohistochemistry
  • 相关文献

参考文献8

  • 1SEIFERT H, GEORGIOU A, ALEXANDER H,et al. Poor perfor-mance status (IXS) is an indication for an aggressive approach to necadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC) [J]. Gynecd Onco/,2015,139(2) :216 -220.
  • 2KIM K H, JELOVAC D, ARMSTRONG D K,et al. Phase lb safety study of farletuzumab, carboplatin and pegylated Lipnsomal doxorubi- tin in patients with platinum - sensitive epithelial ovarian cancer[ J l- Gynecol Onco1,2015,28 ( 15 ) :302 - 331.
  • 3韩肖燕,陈悦,侯敏敏,杨开选,陈莹莹,郄明蓉.上皮性卵巢癌AIB1蛋白表达水平及与雌、孕激素受体表达的相关性研究[J].实用肿瘤杂志,2009,24(4):341-344. 被引量:7
  • 4李庆霞,潘海燕,闫晓路,颜聪亚,苗军程,张炎,王娟,张秀智.AIB1在乳腺良、恶性病变组织中的表达及临床意义[J].实用肿瘤杂志,2012,27(6):593-599. 被引量:1
  • 5SOLi~TORMOS G, DUFFY M J, OTHMAN ABU HASSAN S, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: upda- ted guidelines from the european group on tumor markers [ J ]. lnt J Gynecol Cancer,2016,26 ( 1 ) :43 - 51.
  • 6KARIMI- ZARCHI M, MORTAZAVIZADEH S M, BASHARDUST N, et al. The clinicopathologic characteristics and 5 - year survival rate of epithelial ovarian cancer in Yazd, h'an [ J ]. Electron Physician,2015,7 (6) :1399 - 1406.
  • 7WARGON V, RIGGIO M, GIULIANELLI S,et al. Progestin and an- tiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SKIRT recruitment to the CCND1 and MYC promo- ters[ J]. Iat J Cancer,2015,136( I 1 ) :2680 - 2692.
  • 8朱益平,刘银华,盛莉莉,吉兆宁.AIB1蛋白在卵巢肿瘤中的表达及意义[J].皖南医学院学报,2012,31(6):435-437. 被引量:2

二级参考文献52

  • 1韩肖燕,张雪梅,陈悦,杨开选,郄明蓉.AIB1蛋白在妇科肿瘤中的表达[J].四川大学学报(医学版),2007,38(2):246-249. 被引量:5
  • 2Kuang SQ,Liao L,Wang S,et al.Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis[J].Cancer Res,2005,65(17):7993-8002.
  • 3Liao L,Kuang SQ,Yuan Y,et al.Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1[J].J Steroid Biochem Mol Biol,2002,83(1-5):3-14.
  • 4Henke RT,Haddad BR,Kim SE,et al.Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma[J].Clin Cancer Res,2004,10(18):6134-6142.
  • 5Tanner MM,Grenman S,Koul A,et al.Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer[J].Clin Cancer Res,2000,6(5):1833-1839.
  • 6Anzick SL,Kononen J,Walker RL,et al.AIB1,a steroid receptor coactivator amplified in breast and ovarian cancer[J].Science (Wash.DC),1997,277(5328):965-968.
  • 7Bouras T,Southey MC,Venter DJ.Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu[J].Cancer Res,2001,61(3):903-907.
  • 8Glaeser M,Floetotto T,Hanstein B,et al.Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas[J].Horm Metab Res,2001,33(3):121-126.
  • 9Sakakura C,Hagiwara A,Yasuoka R,et al.Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers[J].Int J Cancer,2000,89(3):217-223.
  • 10Xie D,Sham JS,Zeng WF,et al.Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma[J].Hum Pathol,2005,36(7):777-783.

共引文献6

同被引文献41

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部